Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.

Kathy D Miller; Véronique Diéras; Nadia Harbeck; Fabrice Andre; Reshma L Mahtani; Luca Gianni; Kathy S Albain; Diana Crivellari; Liang Fang; Glenn Michelson; Sanne L de Haas; Howard A Burris

首页> 外文期刊>Journal of Clinical Oncology >Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.

【24h】

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.

机译：Trastuzumab emtansine的IIA IIA试验与人表皮生长因子受体2阳性，局部晚期或转移性乳腺癌的患者。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

T-DM1 and pertuzumab can be combined at full doses with no unexpected toxicities. The preliminary efficacy in patients in the first-line and advanced MBC settings warrants further investigation.

机译：T-DM1和Pertuzumab可以在完全剂量上组合，没有意外的毒性。一线患者初步疗效和先进的MBC设置中的初步疗效认证进一步调查。

著录项

来源
《Journal of Clinical Oncology》 |2014年第14期|共8页
作者
Kathy D Miller; Véronique Diéras; Nadia Harbeck; Fabrice Andre; Reshma L Mahtani; Luca Gianni; Kathy S Albain; Diana Crivellari; Liang Fang; Glenn Michelson; Sanne L de Haas; Howard A Burris;
展开▼
作者单位

Kathy D;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. [J] . Kathy D Miller, Véronique Diéras, Nadia Harbeck, Journal of Clinical Oncology . 2014,第14期

机译：Trastuzumab emtansine的IIA IIA试验与人表皮生长因子受体2阳性，局部晚期或转移性乳腺癌的患者。
2. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial [J] . Rimawi Mothaffar, Ferrero Jean-Marc, de la Haba-Rodriguez Juan, Journal of Clinical Oncology . 2018,第28期

机译：第一线曲妥珠单抗加上芳香酶抑制剂，有或没有Pertuzumab，在人表皮生长因子受体2阳性和激素受体阳性转移或局部晚期乳腺癌（pertain）：一个随机的开放标签期II试验
3. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer [J] . WelslauM., DiérasV., SohnJ.-H., Cancer: A Journal of the American Cancer Society . 2014,第5期

机译：EMILIA的患者报告结果，曲妥珠单抗Emtansine（T-DM1）与卡培他滨和拉帕替尼在人表皮生长因子受体2阳性局部晚期或转移性乳腺癌中的随机3期研究
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population [O] . Shoko Noda-Narita, Akihiko Shimomura, Asuka Kawachi, -1

机译：曲妥珠单抗氨丹宁在仅使用过曲妥珠单抗和帕妥珠单抗联合曲妥珠单抗治疗且仅在日本人群中治疗的转移性人类表皮生长因子受体2阳性乳腺癌患者之间的疗效比较
7. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population [O] . Shoko Noda-Narita, Akihiko Shimomura, Asuka Kawachi, 2019

机译：血液抑制患者患者曲妥珠单抗疗效的疗效比较，所述转移性人体表皮生长因子患者2阳性乳腺癌及仅在日本人群中的曲妥珠单抗治疗

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.

摘要

著录项

相似文献

相关主题

期刊订阅